In The Know: How do KOLs think the atopic dermatitis treatment paradigm will evolve?

New key opinion leader (KOL) research into current and potential atopic dermatitis (AD) therapies is underway. Discussing unmet needs in existing therapies and the potential of pipeline projects with leaders in the field, the results of this research aim to uncover insights on how the treatment landscape will evolve over the next three-to-five years. The research will follow the key lines of inquiry set out below.

Atopic dermatitis key intelligence areas—lines of inquiry

  1. Which products are currently used to treat moderate-to-severe AD?

  2. What do KOLs think of dupilumab and crisaborole, and how are these products currently being used?

  3. How do KOLs view late-stage pipeline therapies, such as tralokinumab, baricitinib and PF- 04965842?

  4. How will these agents be positioned and what impact will they have on the AD treatment algorithm?

  5. Which early-stage therapies are considered the most promising?

  6. How will the AD treatment paradigm evolve over the next five years?

  7. What future role will biomarkers have for informing AD treatment decisions?

 

Submit any questions you have about this research here.


FirstWord conducts similar research in nearly 30 evolving disease areas. Contact us to learn more.

 

 

To read more Sponsored Story articles, click here.

Reference Articles